Don Bryant, Indiana resident, U.S. Army veteran, and prostate cancer survivor who received treatment with Pluvicto™ therapy in clinical trial Philip Low, Purdue Institute for Cancer Research member, ...
Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...
PLYMOUTH MEETING, PA [July 10, 2025] — New research in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results